Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S330000, C514S345000, C514S376000
Reexamination Certificate
active
07153866
ABSTRACT:
The present invention provides a method for the prophylactic and therapeutic treatment of cancer. The method comprises administering to an animal, preferably a mammal, more preferably a human, at risk for developing a cancer or having a cancer a nitroxide or a prodrug thereof, wherein the nitroxide or prodrug thereof preferably is alicyclic or heterocyclic and more preferably is a compound of Formula (I) or Formula (II): in an amount sufficient to prevent or treat said cancer, wherein said cancer is susceptible to prevention or treatment by said nitroxide or prodrug thereof. Also provided is a composition for use in the method
REFERENCES:
patent: 5840734 (1998-11-01), Bernstein
patent: WO 96/40127 (1996-12-01), None
“Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies”, Harris, 1996, 88:1442-55.
“Antitumor activity of a new low immunosuppressive derivative of podophyllotoxin (GP-11) and its mechanism”, Wang et al., 1993, Anti-Cancer Drug Des., 8(3), 193-202.
“NINDS Ataxia Telangiectasia Information Page”, The National Institute of Neurological Disorders and Stroke, NIH, 2003.
“Genetic Testing on Embryos Hits New Milestone”, Matloff, E., Reuters News, 2001.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010. 1996.
“Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia”, Cell, vol. 86, 159-171, Jul. 12, 1996.
“Cancer Chemoprevention by the Antioxidant tempol in Atm-deficient mice”, Schubert et al., Human Molecular Genetics, abstract, 2004, 13(16), 1793-1802.
JAX Mice Data Sheet, www.jaxmice.jax.org, 2006.
Monti et al., “Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Against Different Neoplastic and Non-Neoplastic Cell Lines,”PAACR Annual Meeting, 36, 387 (1995).
Monti et al., “DNA Damage and Apoptosis in Human Leukemic Cells Treated with the Piperidine Nitroxyde Tempol,”PAACR Annual Meeting, 38, 193 (1997).
Monti et al., “The Piperidine Nitroxyde Tempol-Induced Apoptosis and P21-WAF1-CIP1 Expression in P53-Deficient Cells,”PAACR Annual Meeting, 39, 90 (1998).
Cherukuri Murali Krishna
DeLuca Anne Marie
Mitchell James B.
Russo Angelo
Kwon Brian
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Use of tempol for the treatment of Li-Fraumeni syndrome and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tempol for the treatment of Li-Fraumeni syndrome and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tempol for the treatment of Li-Fraumeni syndrome and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711192